Literature DB >> 11166380

Activated T lymphocytes from patients with high risk of type I diabetes mellitus have different ability to produce interferon-gamma, interleukin-6 and interleukin-10 and undergo anti-CD95 induced apoptosis after insulin stimulation.

H Tchórzewski1, E Głowacka, M Banasik, P Lewkowicz, M Szałapska-Zawodniak.   

Abstract

Type I Diabetes mellitus (DM1) is the effect of T cell dependent autoimmune destruction of insulin producing beta cells in the pancreas islet. T cells are activated in response to islet dominant autoantigens, the result being the development of DM1. Insulin is one of the islet autoantigens responsible for activation of T lymphocyte functions, inflammatory cytokine production and development of DM1. The experiments reported in this study have shown the spontaneous increase of CD95 molecule expression on lymphocytes of the first-degree relatives of DM1 patients. The autoantigen insulin is responsible for stimulation in vitro of potentially hazardous 'memory' lymphocytes to produce interleukin-6 (IL-6) and interleukin-10 (IL-10) interleukins. Insulin induced stimulation of lymphocytes in vitro was observed in patients at high risk of developing diabetes mellitus (prediabetics). Phytohaemagglutinin (PHA) stimulates lymphocytes of all groups in the same way. Stimulated lymphocytes in second cultures undergo apoptosis induced with anti-Fas specific antibodies. The deletion in vitro of resting peripheral lymphocytes is nonfunctional. Insulin activated T lymphocytes, which undergo apoptosis were not observed in peripheral blood of healthy people and in patients with DM1. This observation suggests that insulin is involved as autoantigen in DM1 progression in patients with high risk of diabetes type I. The autoreactive T lymphocytes may persist in peripheral blood of patients with high risk DM1. Defective elimination of autoreactive T cells may result in autodestructive damage of islets beta cells in the prediabetic stage and disease progression to DM1.

Entities:  

Mesh:

Substances:

Year:  2001        PMID: 11166380     DOI: 10.1016/s0165-2478(00)00309-6

Source DB:  PubMed          Journal:  Immunol Lett        ISSN: 0165-2478            Impact factor:   3.685


  5 in total

1.  Assessment of human lymphocyte proliferation associated with metabolic syndrome.

Authors:  O A Pinzón; J C Sánchez; J C Sepúlveda-Arias; D F López-Zapata
Journal:  J Endocrinol Invest       Date:  2015-05-16       Impact factor: 4.256

2.  Cytokine secretion in long-standing diabetes mellitus type 1 and 2: associations with low-grade systemic inflammation.

Authors:  Krystallenia I Alexandraki; Christina Piperi; Panayiotis D Ziakas; Nikolaos V Apostolopoulos; Konstantinos Makrilakis; Vassiliki Syriou; Evanthia Diamanti-Kandarakis; Gregory Kaltsas; Anastasios Kalofoutis
Journal:  J Clin Immunol       Date:  2008-01-26       Impact factor: 8.317

3.  Serum IL-1beta, IL-2, and IL-6 in insulin-dependent diabetic children.

Authors:  Yasar Dogan; Saadet Akarsu; Bilal Ustundag; Erdal Yilmaz; Metin Kaya Gurgoze
Journal:  Mediators Inflamm       Date:  2006       Impact factor: 4.711

4.  Recombinant HBsAg of the Wild-Type and the G145R Escape Mutant, included in the New Multivalent Vaccine against Hepatitis B Virus, Dramatically Differ in their Effects on Leukocytes from Healthy Donors In Vitro.

Authors:  Maria V Konopleva; Vera N Borisova; Maria V Sokolova; Tatyana A Semenenko; Anatoly P Suslov
Journal:  Vaccines (Basel)       Date:  2022-02-03

5.  The involvement of T lymphocytes in the pathogenesis of endometriotic tissues overgrowth in women with endometriosis.

Authors:  Krzysztof Szyllo; Henryk Tchorzewski; Malgorzata Banasik; Ewa Glowacka; Przemyslaw Lewkowicz; Anna Kamer-Bartosinska
Journal:  Mediators Inflamm       Date:  2003-06       Impact factor: 4.711

  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.